If the level of ALT is elevated at least 1.5 times, that is the criterion for enrollment in a clinical trial, but ALT has only 51% sensitivity for the diagnosis of NASH [1,107]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.